About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

It should be noted that Auvation Ltd had out-licensed certain uses of one of its
P450 targets to Zycos Inc. of Lexington, MA, now part of MGI Pharma, Inc.
(NASDAX: MOGN). A cancer vaccine based on the IP licensed from Auvation is
scheduled to enter Phase II clinical trials in Q1 2006. Substantial revenues
can potentially flow from this deal, with milestones paid on entry to each
clinical trial phase, and royalties payable on sales when the drug comes to
market.


The Company has leading expertise in the science of apoptosis (or "programmed
cell death") and is at the forefront of efforts to control this critical
cellular mechanism in order to treat cancer. EiRx has three active programmes
developing drugs that trigger tumour cell death by activating apoptosis. Two of
these are the collaborations with OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and
Sareum mentioned above. Both these initiatives are in the assay development and
screening stages, and are expected to achieve scheduled milestones in early to
mid 2006.

EiRx Therapeutic to get 1st milestone payment as OSI licenses 4 drug targets

LONDON (AFX) - EiRx Therapeutics PLC, the healthcare company specialising in
the control of programmed life and death of cells (apoptosis), said OSI
Pharmaceuticals has opted to license four of its drug targets, thereby
triggering first milestone payment with a potential value of up to 18.8 mln usd.
In a statement, the company said OSI Pharmaceuticals has opted to license
and take forward four of its gene targets into drug discovery for oncology.
A success fee for each target is payable by OSI Pharmaceuticals, as part of
a deal consisting of upfront access and consultancy fees, potential success fees
for each target elected by OSI Pharmaceuticals to license and potential
milestone payments based on successful commercialisation of a novel therapeutic
with respect to each such target.
newsdesk@afxnews.com
http://www.advfn.com/p.php?pid=nmona&cb=1161174802&article=7554608&symbol=LSE%3AERX

Potatohead you have excelled yourself!!!

Not often I trust on other peoples research but I repurchased this morning on a rising price - against all my normal instincts.

Thanks!

I would hold even if news comes laurie, there is more than one bit of news to come in the short term..

OSI, MGI and breast cancer!!!! and then there are the patent approvals, which are now due

Someone just sold at 0.030 and yet mm put the price down to 0.025?

ignore it.. they are short of shares, they dont want anymore buying.. they are scared.. dont blame em, rumour is these are going to 8p

when you think on the breast cancer news we went up to 40, yet today we struggle to get there on the expectation of huge sums of money!!!.. quite rediculous how the mm's play it really, as per John pools interview, the mm's dont understand what the company does and so therefore does not know the value..

and as per j Pool, the SP is significantly undervalued, when he said this the SP was standing at 35.. so we have not even really gone up since he said the sp is undervalued...

says alot really dont it
http://www.wallstreetreporter.com/interview.php?id=18589&player=wma

PH
Can you keep your ramping slightly down or better still on the other side the stuff you have posted above is from 05 May 2004. The OSI website states OSI-930 as finished Phase 1 - not started Phase 2 and OSI-817 as IND-TRACKED (not at phase 1 yet) and states "OSI-817 is a second development candidate to arise from our c-kit/VEGFR program and this molecule could enter clinical development by year end." the sp is rising on speculation of a new deal in addition to any payments that may come from OSI

I,m getting sea sick all this up and downing but at least it's blue!

:-) dont worry, we are on the launch pad.. tomorrow we will be taking off

Good night PH.

Well done.

Does anyone know when the confirmation is due on milestone payment?

Soon with luck !

Nothing but increased buys all morning and the mm put the price down!

IMHO It will up & down like H... draws till news ! : )

MGI has put 30mil USD aside for licence payments for the current qtr

some of that is bound to be for us

Morning pot head :)

The sp is gathering momentum I think we will see a steady increase over the weeks to come just based on rumour and any anticipated RNS if you look back over previous RNSS, Newss, Collaboration with bioMerieux, Acquisition of Auvation, EiRx and Merck Sign Agreement, Possible Milestone Payments from OSI Pharmaceuticals, and the latest news Positive Breast Cancer Data, the news is always positive ERX is moving forward and now getting noticed by the bigger players in the Phama, bio industry and by investors. This has all the makings of a multi bagger, any small movements in the sp is irrelevant at the end of the day there is only one way the sp is heading IMO and thats north.

Just in time for xmas :) nice one driver (GTL NEXT )

Over 10Mil Buys Can't believe there there still a couple of red arrows from the MM's